Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan

Abstract Background The incidence of prostate cancer is increasing in Asian countries. Although moderately hypofractionated radiotherapy is not inferior to conventional fractionated radiation according to the updated guidelines, data regarding its efficacy and safety in Taiwan are currently lacking....

Full description

Saved in:
Bibliographic Details
Main Authors: Hui-Lei Mu, Mau-Shin Chi, Hui-Ling Ko, Guang-Dar Juang, Thomas I-Sheng Hwang, Kwan-Hwa Chi, Kai-Lin Yang
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Urology
Subjects:
Online Access:https://doi.org/10.1186/s12894-024-01661-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585339459338240
author Hui-Lei Mu
Mau-Shin Chi
Hui-Ling Ko
Guang-Dar Juang
Thomas I-Sheng Hwang
Kwan-Hwa Chi
Kai-Lin Yang
author_facet Hui-Lei Mu
Mau-Shin Chi
Hui-Ling Ko
Guang-Dar Juang
Thomas I-Sheng Hwang
Kwan-Hwa Chi
Kai-Lin Yang
author_sort Hui-Lei Mu
collection DOAJ
description Abstract Background The incidence of prostate cancer is increasing in Asian countries. Although moderately hypofractionated radiotherapy is not inferior to conventional fractionated radiation according to the updated guidelines, data regarding its efficacy and safety in Taiwan are currently lacking. The aim of this study was to investigate the outcomes of prostate cancer patients treated with hypofractionated image-guided radiotherapy at a single institution in Taiwan. Methods We retrospectively included patients with prostate cancer across all risk groups who were treated with hypofractionated image-guided radiotherapy 70 Gy (Gy) in 28 fractions (at 2.5 Gy/fraction) between 2007 and 2022. We analyzed treatment efficacy by assessing overall survival, prostate cancer-specific survival, event-free survival, biochemical failure, locoregional recurrence, and distant metastasis. The safety of the treatment was evaluated through acute and late gastrointestinal (GI) and genitourinary (GU) toxicity grading based on the Radiation Therapy Oncology Group criteria. Event-free survival, overall survival, prostate cancer-specific survival, biochemical failure, locoregional recurrence, and distant metastasis were evaluated using the Kaplan–Meier method. Results We identified 150 consecutive men with prostate cancer: 12.7% were at low risk, 32.7% were at intermediate risk, 44.6% were at high risk, and 10% had N1 disease. The median follow-up time was 68.9 months (range: 2.3–172 months). The 5-year overall survival rate was 91.7% for the entire cohort, with rates of 100%, 94.3%, 93.3% and 71.1% for the low-risk, intermediate-risk, high-risk, and N1-disease groups, respectively (p < 0.001). The 5-year event-free survival rate for all patients was 75.8%. Among the risk groups, the 5-year event-free survival rates were 100%, 86.3%, 68.3% and 52.5% for the low-risk, intermediate-risk, high-risk, and N1 disease groups, respectively (p < 0.001). Grade ≥ 2 late GI toxicity was rare (0.7%), and grade ≥ 2 late GU toxicity was observed in 9.3% of the patients. Conclusions Hypofractionated image-guided radiotherapy, delivering 70 Gy at 2.5 Gy per fraction, is both effective and safe for Taiwanese patients with prostate cancer across all risk groups, consistent with findings from existing large randomized trials. Therefore, as a solution to enhance patient convenience, hypofractionated radiotherapy is a reasonable option for the definitive treatment of prostate cancer. Trial registration Not applicable.
format Article
id doaj-art-22a219ce88134b50b1e0576f25612e93
institution Kabale University
issn 1471-2490
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Urology
spelling doaj-art-22a219ce88134b50b1e0576f25612e932025-01-26T12:54:13ZengBMCBMC Urology1471-24902025-01-012511810.1186/s12894-024-01661-yHypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in TaiwanHui-Lei Mu0Mau-Shin Chi1Hui-Ling Ko2Guang-Dar Juang3Thomas I-Sheng Hwang4Kwan-Hwa Chi5Kai-Lin Yang6Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial HospitalDepartment of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial HospitalDepartment of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial HospitalDivision of Urology, Department of Surgery, Shin Kong Wu Ho-Su Memorial HospitalDivision of Urology, Department of Surgery, Shin Kong Wu Ho-Su Memorial HospitalDepartment of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial HospitalDepartment of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial HospitalAbstract Background The incidence of prostate cancer is increasing in Asian countries. Although moderately hypofractionated radiotherapy is not inferior to conventional fractionated radiation according to the updated guidelines, data regarding its efficacy and safety in Taiwan are currently lacking. The aim of this study was to investigate the outcomes of prostate cancer patients treated with hypofractionated image-guided radiotherapy at a single institution in Taiwan. Methods We retrospectively included patients with prostate cancer across all risk groups who were treated with hypofractionated image-guided radiotherapy 70 Gy (Gy) in 28 fractions (at 2.5 Gy/fraction) between 2007 and 2022. We analyzed treatment efficacy by assessing overall survival, prostate cancer-specific survival, event-free survival, biochemical failure, locoregional recurrence, and distant metastasis. The safety of the treatment was evaluated through acute and late gastrointestinal (GI) and genitourinary (GU) toxicity grading based on the Radiation Therapy Oncology Group criteria. Event-free survival, overall survival, prostate cancer-specific survival, biochemical failure, locoregional recurrence, and distant metastasis were evaluated using the Kaplan–Meier method. Results We identified 150 consecutive men with prostate cancer: 12.7% were at low risk, 32.7% were at intermediate risk, 44.6% were at high risk, and 10% had N1 disease. The median follow-up time was 68.9 months (range: 2.3–172 months). The 5-year overall survival rate was 91.7% for the entire cohort, with rates of 100%, 94.3%, 93.3% and 71.1% for the low-risk, intermediate-risk, high-risk, and N1-disease groups, respectively (p < 0.001). The 5-year event-free survival rate for all patients was 75.8%. Among the risk groups, the 5-year event-free survival rates were 100%, 86.3%, 68.3% and 52.5% for the low-risk, intermediate-risk, high-risk, and N1 disease groups, respectively (p < 0.001). Grade ≥ 2 late GI toxicity was rare (0.7%), and grade ≥ 2 late GU toxicity was observed in 9.3% of the patients. Conclusions Hypofractionated image-guided radiotherapy, delivering 70 Gy at 2.5 Gy per fraction, is both effective and safe for Taiwanese patients with prostate cancer across all risk groups, consistent with findings from existing large randomized trials. Therefore, as a solution to enhance patient convenience, hypofractionated radiotherapy is a reasonable option for the definitive treatment of prostate cancer. Trial registration Not applicable.https://doi.org/10.1186/s12894-024-01661-yProstate cancerHypofractionationImage-guided radiotherapyTreatment toxicities
spellingShingle Hui-Lei Mu
Mau-Shin Chi
Hui-Ling Ko
Guang-Dar Juang
Thomas I-Sheng Hwang
Kwan-Hwa Chi
Kai-Lin Yang
Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
BMC Urology
Prostate cancer
Hypofractionation
Image-guided radiotherapy
Treatment toxicities
title Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
title_full Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
title_fullStr Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
title_full_unstemmed Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
title_short Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan
title_sort hypofractionated image guided radiotherapy with 70 gy in 28 fractions for prostate cancer confined to the pelvis a single institute experience in taiwan
topic Prostate cancer
Hypofractionation
Image-guided radiotherapy
Treatment toxicities
url https://doi.org/10.1186/s12894-024-01661-y
work_keys_str_mv AT huileimu hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT maushinchi hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT huilingko hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT guangdarjuang hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT thomasishenghwang hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT kwanhwachi hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan
AT kailinyang hypofractionatedimageguidedradiotherapywith70gyin28fractionsforprostatecancerconfinedtothepelvisasingleinstituteexperienceintaiwan